Nasdaq
$6.25▲ 1.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $183.6MShares out 29.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 9.29Pre-market26.09.29 20:338-KKey event#●●●#●●●#●●●
Cartesian Therapeutics, Inc.Bullish
Cartesian Therapeutics announced positive Phase 2 retreatment data for its lead candidate, Descartes-08, in patients with myasthenia gravis (MG). All five retreated patients showed clinically meaningful symptom improvement and sustained efficacy through 12 months without new safety concerns. The company expects to report topline results from the Phase 3 AURORA trial in the first quarter of 2027.…more
$6.25+1.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.6Pre-market26.08.06 20:0510-QEarnings
Cartesian Therapeutics, Inc.
Cartesian Therapeutics는 2026년 2분기 실적 보고를 통해 2026년 5월 22일 체결된 대출 및 담보 계약을 포함한 재무 상태를 공시했습니다. 해당 분기 동안 회사는 주식 보상 계획 및 전환사채 등 자본 구조 변경 사항을 반영하였으며, 임직원 유인 인센티브 보상 계획을 개정 및 재설정하였습니다.…more
$6.25+1.13%vs prev closeView filingShare - 8.6Pre-market26.08.06 20:038-KKey event
Cartesian Therapeutics, Inc.
Cartesian Therapeutics는 2026년 2분기 실적 발표를 통해 1억 4,930만 달러의 현금성 자산을 확보하여 2028년까지 운영 자금을 마련했다고 밝혔다. 주력 파이프라인인 Descartes-08의 임상 3상 데이터가 2027년 1분기에 도출될 예정이며, WestGene과의 신규 전략적 파트너십을 통해 체내(in vivo) CAR-T 플랫폼 개발을 가속화한다.…more
$6.25+1.13%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.2Pre-market26.10.02 20:00#●●●
Cartesian Therapeutics Grants Employment Inducement Stock Options
Cartesian Therapeutics has issued stock options for 121,900 shares to four new employees as an employment inducement. This is a standard incentive grant for talent acquisition and does not have a material impact on the company's valuation.…more
$6.25+1.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.29Pre-market26.09.29 20:30
●●●●●●●● ●●●●● ●●●●●●
Cartesian Therapeutics announced that retreatment with Descartes-08 demonstrated sustained symptom improvement and a favorable safety profile in patients with myasthenia gravis. These findings support the company's progress toward the topline results of its Phase 3 AURORA trial expected in 1Q27.…more
$6.25+1.13%vs prev close - 9.3Pre-market26.09.03 20:00
●●●●●●●● ●●●●● ●●●●●●
Cartesian Therapeutics announced its participation in several upcoming healthcare investor conferences throughout September. These scheduled appearances are routine investor relations activities and do not provide immediate catalysts for the stock.…more
$6.25+1.13%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report